S87 Severe asthma outcomes when switching from mepolizumab to benralizumab in non-responders with persistent sputum eosinophilia

Abstract

QUEST experienced fewer exacerbations during both studies. Over 80% of patients who achieved 100mL or 200mL pre-bronchodilator FEV1 improvements at the end of QUEST maintained these improvements in TRAVERSE. Conclusions Greater improvements in pre-bronchodilator FEV1 in QUEST led to long-term enhanced benefits of dupilumab treatment; patients maintained these improvements and had fewer exacerbations during TRAVERSE.